BGP 15

03/01/2014 - "Improvement of insulin sensitivity by a novel drug candidate, BGP-15, in different animal studies."
06/01/2014 - "In addition, the HSP72 coinducer BGP-15, currently in human clinical trials for type 2 diabetes, also increased mitochondrial number and insulin sensitivity in a rat model of type 2 diabetes. "
05/01/2009 - "BGP-15 at 200 or 400 mg significantly improved insulin sensitivity in insulin-resistant, nondiabetic patients during treatment compared to placebo and was safe and well-tolerated. "
01/01/2018 - "BGP-15, a hydroxylamine derivative, prevents insulin resistance in humans and protects against several oxidative stress-related diseases in animal models. "
03/01/2014 - "BGP-15 doses of 10 and 30 mg/kg increased insulin sensitivity by 50% and 70%, respectively, in cholesterol-fed but not in normal rabbits. "

01/01/2023 - "Retracted: Modulation of Mitochondrial Quality Control Processes by BGP-15 in Oxidative Stress Scenarios: From Cell Culture to Heart Failure."
01/01/2022 - "The small molecule BGP-15 has been reported to alleviate symptoms of heart failure and improve muscle function in murine models. "
01/01/2021 - "Modulation of Mitochondrial Quality Control Processes by BGP-15 in Oxidative Stress Scenarios: From Cell Culture to Heart Failure."
01/01/2021 - "BGP-15 Protects against Heart Failure by Enhanced Mitochondrial Biogenesis and Decreased Fibrotic Remodelling in Spontaneously Hypertensive Rats."
01/01/2021 - "In our recent work, we aimed to clarify the mitochondrial protective effects of BGP-15 in a hypertension-induced heart failure model and "in vitro." Spontaneously hypertensive rats (SHRs) received BGP-15 or placebo for 18 weeks. "

03/01/2006 - "The in vivo administration of BGP-15 resulted in a decrease in tumor weight and mitotic index, while it did not affect the apoptotic rate in the xenograft. "
03/01/2006 - "Hence, the effect of BGP-15 on angiogenesis was studied in Hepa 1c1c7 tumor xenografts. "
03/01/2006 - "One group of animals was given 100 mg/kg body weight/day BGP-15 intraperitoneally during tumor development. "
03/15/2002 - "On the other hand, BGP-15 did not inhibit the antitumor efficacy of cisplatin in cell culture and in transplantable solid tumors of mice. "
04/01/2013 - "Importantly, we found that both the new analog BGP-13 and also BGP-15, another calcipotriene-based analog we synthesized previously and about which we published recently, inhibit the growth of HT-29 tumor xenografts in nude mice."

09/01/2011 - "Heat shock, or pre-treatment with HSP-inducers GGA and BGP-15, resulted in endogenous HSP overexpression and protection against tachycardia remodeling. "
02/26/2023 - "BGP-15 failed to counteract 1 mg/kg ISO-induced tachycardia, but diminished the ECG of ischemia and suppressed ventricular arrhythmia incidence. "

01/01/2021 - "In our recent work, we aimed to clarify the mitochondrial protective effects of BGP-15 in a hypertension-induced heart failure model and "in vitro." Spontaneously hypertensive rats (SHRs) received BGP-15 or placebo for 18 weeks. "
01/01/2021 - "The mitigation of remodelling processes and the preserved systolic cardiac function in hypertension-induced heart failure can be a result-at least partly-of the enhanced mitochondrial biogenesis caused by BGP-15."
01/01/2021 - "Our recent work was aimed at examining the effects of BGP-15 in a chronic hypertension-induced heart failure model. "